1-[4-(morpholino)butyryloxy]-3-n-pentyl-6,6,9-trimethyl-10a,6a,7,8-tetrahydrodibenzo[b,d]pyran hydrochloride | 39590-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-[4-(morpholino)butyryloxy]-3-n-pentyl-6,6,9-trimethyl-10a,6a,7,8-tetrahydrodibenzo[b,d]pyran hydrochloride
• 英文别名: (6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl) 4-morpholin-4-ylbutanoate;hydrochloride
• CAS: 39590-61-9
• 化学式: C₂₉H₄₃NO₄*ClH
• 分子量: 506.126
• InChiKey: UBKGHMMUMBSCMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.47
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  D9四氢大麻酚 、 4-(4-吗啉基)丁酸盐酸盐 、 N,N'-二环己基碳二亚胺 、 二氯甲烷 在 N,N-二环己脲 、 二氯甲烷 、 苯 、 benzene pet ether 作用下， 以 chloroform methanol 为溶剂， 反应 40.0h， 以to give 0.7 g的产率得到1-[4-(morpholino)butyryloxy]-3-n-pentyl-6,6,9-trimethyl-10a,6a,7,8-tetrahydrodibenzo[b,d]pyran hydrochloride
  参考文献：
  名称：

  Anesthesia methods using benzopyrans and esters thereof as

  摘要：

  改进的麻醉方法包括使用式I的苯并吡喃预处理待麻醉的患者，其中在C环中，X为NR.sub.1，S，CH.sub.2或##STR2##，R.sub.1为氢，低烷基，低烯基，低炔基，低酰基，环烷基低烷基，环烷基低酰基，环烷基，卤代低烷基，卤代低烯基，苯基低烷基，苯基低烯基或苯基低烷基基；m为0至3的整数，n为0至3的整数，n + m = 2或3；或C环为喹啉环##STR3##，R.sub.2为低烷基；R.sub.3为氢或##STR4##，其中Y为直链或支链烷基链，具有1至8个碳原子，a为1至4的整数，b为1至4的整数，Z为CH.sub.2，O，S或NR.sub.6，其中R.sub.6为氢或低烷基，限制条件为当Z为O，S或NR.sub.5时，a和b的和为3或4，R.sub.5为氢或低烷基；R.sub.4为C.sub.1-C.sub.20直链或支链烷基，环烷基，或##STR5##，其中Y为具有1至10个碳原子的直链或支链烷基链，每个R.sub.7，R.sub.8和R.sub.9是相同或不同的羟基，卤素，三氟甲基或低烷基成员的群；及其药学上可接受的盐，限制条件为当X为##STR6##时，m = 2且n = 2时，R.sub.3不能为氢。

  公开号：

  US04025630A1

文献信息

• Heterocyclic esters of benzopyrans
  申请人：Sharps Associates

  公开号：US03941782A1

  公开（公告）日：1976-03-02

  This invention relates to novel esters of benzopyrans represented by the formulae ##SPC1## Wherein R and R' are hydrogen or C.sub.1 -C.sub.6 alkyl and when alkyl are on the same or different carbons; R.sub.1 is C.sub.1 -C.sub.6 alkyl; R.sub.2 is C.sub.1 -C.sub.20 alkyl, lowercycloalkyloweralkyl or lowercycloalkyl; n is an integer from 3 to 7, and particularly 3 to 5; Y is a straight or branched chain C.sub.1 -C.sub.8 alkylene; and R.sub.3 is ##EQU1## WHEREIN A IS AN INTEGER FROM 1 TO 4, B IS AN INTEGER FROM 1 TO 4, X is O,S, CH.sub.2 or NR.sub.4 and R.sub.4 is hydrogen C.sub.1 -C.sub.6 alkyl, and R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; and the acid addition salts thereof. The compounds exhibit analgesic and central nervous system activity.

  本发明涉及一种新型苯并吡喃酸酯，其化学式为：##SPC1## 其中，R和R'为氢或C.sub.1-C.sub.6烷基，当烷基在同一或不同碳上时；R.sub.1为C.sub.1-C.sub.6烷基；R.sub.2为C.sub.1-C.sub.20烷基，较低的环烷基较低的烷基或较低的环烷基；n为3至7的整数，特别是3至5；Y为直链或支链C.sub.1-C.sub.8烷基；R.sub.3为##EQU1## 其中，A为1至4的整数，B为1至4的整数，X为O、S、CH.sub.2或NR.sub.4，R.sub.4为氢C.sub.1-C.sub.6烷基，R.sub.5为氢或C.sub.1-C.sub.6烷基；以及其酸盐加合物。这些化合物表现出镇痛和中枢神经系统活性。
• US3941782A
  申请人：——

  公开号：US3941782A

  公开（公告）日：1976-03-02
• US4025630A
  申请人：——

  公开号：US4025630A

  公开（公告）日：1977-05-24
• Anesthesia methods using benzopyrans and esters thereof as
  申请人：Abbott Laboratories

  公开号：US04025630A1

  公开（公告）日：1977-05-24

  Improved anesthesia methods comprising pretreating a patient to be anesthetized with a benzopyran of formula I ##STR1## wherein, in the C ring, X is NR.sub.1, S, CH.sub.2 or ##STR2## R.sub.1 is hydrogen, loweralkyl, loweralkenyl, loweralkynyl, loweralkanoyl, cycloalkyloweralkyl, cycloalkylloweralkanoyl, cycloalkyl, haloloweralkyl, haloloweralkenyl, phenylloweralkyl, phenyloweralkenyl or phenyloweralkylnyl; m is an integer from 0 to 3, n is an integer from 0 to 3 and n + m = 2 or 3; or the C ring is quinuclidine ring ##STR3## R.sub.2 is loweralkyl; R.sub.3 is hydrogen or ##STR4## wherein Y is a straight or branched chain alkylene group having from one to eight carbon atoms, a is an integer from 1 to 4, b is an integer from 1 to 4, Z is CH.sub.2, O, S or NR.sub.6, R.sub.6 being hydrogen or loweralkyl, with the limitation that when Z is O, S or NR.sub.5, the sum of a and b is 3 or 4, and R.sub.5 is hydrogen or loweralkyl; R.sub.4 is C.sub.1 -C.sub.20 straight or branched chain alkyl, cycloalkyl, or ##STR5## wherein Y is a straight or branched chain alkylene group having from one to ten carbon atoms, and each R.sub.7, R.sub.8 and R.sub.9 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl; and the pharmaceutically acceptable salts thereof, with the limitation that when X is ##STR6## m = 2 and n = 2, R.sub.3 cannot be hydrogen.

  改进的麻醉方法包括使用式I的苯并吡喃预处理待麻醉的患者，其中在C环中，X为NR.sub.1，S，CH.sub.2或##STR2##，R.sub.1为氢，低烷基，低烯基，低炔基，低酰基，环烷基低烷基，环烷基低酰基，环烷基，卤代低烷基，卤代低烯基，苯基低烷基，苯基低烯基或苯基低烷基基；m为0至3的整数，n为0至3的整数，n + m = 2或3；或C环为喹啉环##STR3##，R.sub.2为低烷基；R.sub.3为氢或##STR4##，其中Y为直链或支链烷基链，具有1至8个碳原子，a为1至4的整数，b为1至4的整数，Z为CH.sub.2，O，S或NR.sub.6，其中R.sub.6为氢或低烷基，限制条件为当Z为O，S或NR.sub.5时，a和b的和为3或4，R.sub.5为氢或低烷基；R.sub.4为C.sub.1-C.sub.20直链或支链烷基，环烷基，或##STR5##，其中Y为具有1至10个碳原子的直链或支链烷基链，每个R.sub.7，R.sub.8和R.sub.9是相同或不同的羟基，卤素，三氟甲基或低烷基成员的群；及其药学上可接受的盐，限制条件为当X为##STR6##时，m = 2且n = 2时，R.sub.3不能为氢。